- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02646111
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors ("PI") Failures
An Open-label, Multi-center Study to Evaluate Sustained Virologic Response With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Genotype 1 Chronic Hepatitis C Virus Infected Patients With Past PI Failure
The purpose of this study is to evaluate the efficacy and safety of triple therapy of AbbVie adults with chronic hepatitis C virus ("HCV"), who have not responded to prior treatment with protease inhibitors.
The "Triple therapy" of AbbVie attacks various sites of the viral genome, thus increasing the potential efficacy of the treatment, especially for patients who have failed PI treatment.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Patients with genotype 1 HCV, who underwent past triple therapy (Telaprevir, Boceprevir or Simeprevir with Pegylated interferon / Ribavirin) and are non-responders, partial responders or in relapse - will be screened in all research centers up to 30 days before the first treatment.
At the end of the initial assessment - the recruited participants will be allocated to different treatment groups in accordance with the hepatitis virus subtype 1a, 1b and presence of cirrhosis, as follows:
- Group A - genotype 1b without cirrhosis - 12 weeks of treatment *
- Group B - genotype 1b with cirrhosis - 12 weeks of treatment
- Group C - genotype 1a without cirrhosis - 12 weeks of treatment
- Group D - genotype 1a with cirrhosis - 24 weeks of treatment
(* Only this group will not get Ribavirin)
During the treatment period, participants will be asked to describe the treatment's tolerability (in terms of side effects) using self-administered questionnaires: SF-36, and WPAI Hep C v2.0.
The follow up will also include physical assessments, side effects documentation, blood tests, abdominal Ultrasound and Fibroscan.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
- Navn: Oren Shibolet, MD
- Telefonnummer: 97236973984
- E-mail: orensh@tlvmc.gov.il
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosis of hepatitis C, genotype 1A or 1B.
- Documentation of PI failure of treatment at least 12 months prior to study entry.
- Patients with cirrhosis - (only patients with cirrhosis Child A with only 5 points).
Exclusion Criteria:
- Inability to stay in the study for 36 weeks.
- Diagnosis of cross-contamination by HIV or Hepatitis B virus.
- Renal disfunction (creatinine clearance <30 ml / min).
- Evidence of hepatic carcinoma.
- Another serious disease, which may interfere with the study.
- Pregnant / breast-feeding women.
- Men with pregnant partners.
- Drug or alcohol abuse in the six months preceding the study.
- Chronic liver disease other than hepatitis C (such as Primary biliary cirrhosis, Primary sclerosing cholangitis, Autoimmune hepatitis).
- Current other treatment for HCV.
- Past PI Failure due to adverse events.
- Patients with cirrhosis Child B.
- Patients with cirrhosis, who were at child B and improved to child A after treatment.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Genotype 1b without cirrhosis
12 weeks without Ribavirin
|
12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.
Andre navne:
|
Eksperimentel: Genotype 1b with cirrhosis
12 weeks with Ribavirin
|
12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
Andre navne:
|
Eksperimentel: Genotype 1a without cirrhosis
12 weeks with Ribavirin
|
12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
Andre navne:
|
Eksperimentel: Genotype 1a with cirrhosis
24 weeks with Ribavirin
|
24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
"SVR" (sustained virologic response) rates
Tidsramme: 12 weeks after end of treatment
|
Sustained virologic response
|
12 weeks after end of treatment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
"SF" (short-form)-36 health survey
Tidsramme: Day 1, weeks 4, 12, 24, 36.
|
psychometrically-based physical and mental health and a preference-based health utility index.
|
Day 1, weeks 4, 12, 24, 36.
|
WPAI Hep C v2.0 questionnaire
Tidsramme: Day 1, weeks 4, 12, 24, 36.
|
a scoring manual for work productivity and activity impairment assessment.
|
Day 1, weeks 4, 12, 24, 36.
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i fordøjelsessystemet
- RNA-virusinfektioner
- Virussygdomme
- Infektioner
- Blodbårne infektioner
- Overførbare sygdomme
- Leversygdomme
- Flaviviridae infektioner
- Hepatitis, viral, menneskelig
- Enterovirus infektioner
- Picornaviridae infektioner
- Hepatitis
- Hepatitis A
- Hepatitis C
- Molekylære mekanismer for farmakologisk virkning
- Anti-infektionsmidler
- Antivirale midler
- Antimetabolitter
- Ribavirin
Andre undersøgelses-id-numre
- TASMC-15-OS-503-CTIL
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Hepatitis C
-
Tripep ABInovio PharmaceuticalsUkendtKronisk hepatitis C virusinfektionSverige
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsTrukket tilbageKronisk hepatitis C virusinfektionIsrael
-
Hadassah Medical OrganizationUkendtKronisk hepatitis C virusinfektionIsrael
-
Beni-Suef UniversityAfsluttetKronisk hepatitis C virusinfektionEgypten
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV) | Hepatitis C viral infektionForenede Stater, New Zealand
-
Trek Therapeutics, PBCAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 4 | Hepatitis C viral infektionForenede Stater
-
AbbVieAfsluttetKronisk hepatitis C | Hepatitis C (HCV) | Hepatitis C genotype 1a
-
AbbVie (prior sponsor, Abbott)AfsluttetKronisk hepatitis C | Hepatitis C genotype 1 | Hepatitis C (HCV)Forenede Stater, Australien, Canada, Frankrig, Tyskland, New Zealand, Puerto Rico, Spanien, Det Forenede Kongerige
-
Humanity and Health Research CentreBeijing 302 HospitalAfsluttetKronisk hepatitis C-infektionKina
-
AbbVieAfsluttetHepatitis C virus | Kronisk hepatitis C-virus
Kliniske forsøg med 12 weeks without Ribavirin
-
Germans Trias i Pujol HospitalFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y...Afsluttet
-
Azienda Ospedaliera San Camillo ForlaniniAfsluttet
-
Right to CareBoston University; University of California, Los Angeles; Ministry of Health... og andre samarbejdspartnereAfsluttetHIV-infektioner | Hepatitis B | Hepatitis CMyanmar
-
Biolex Therapeutics, Inc.AfsluttetHepatitis C, kroniskForenede Stater, Bulgarien, Puerto Rico, Rumænien
-
Humanity and Health Research CentreBeijing 302 Hospital; Nanfang Hospital of Southern Medical UniversityRekrutteringKronisk hepatitis C-infektionKina